1Neve BP, Fruchart JC, Staels B, et al. Role of the peroxisome proliferator-activated reeeptors (PPAR) in atherosclerosis [J].Biochem Pharmacol, 2000, 60: 1245-1250.
2Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha)reduce myocardial infarct size[J]. FASEB J,2002, 16: 1027-1040.
3Palojoki E, Saraste A, Eriksson A, et al. Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rots[J]. Am J Physiol Heart Circ Physiol, 2001,280: H2726-H2731.
5Liu HR, Tao L, Gao E, et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion[J]. Cardiovasc Res,2004, 62: 135-144.
6Khandoudi N, Delerive P, Berrebi-Bertrand I, et al. Rosiglitazone,a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury[J]. Diabetes, 2002,51 : 1507-1514.
7Yue TL, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator - activated receptor γ agonist rosiglitazone [J]. Circulation, 2001, 104: 588-594
8Ito H, Nakano A, Kinoshita M, et al. Pioglitazone, a peroxisome proliferator-aetivated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model[J]. Lab Invest,2003,83:1715-1721.
9Shiomi T, Tsutsui H,Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activatod receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction [J]. Circulation, 2002,106 : 3126-3132.
3Thiemermann C, Zacharowski K. Selective activation of E-type prostanoid(3)-3 receptors reduces myocardial infarct size: a novel insight into the cardioprotective effects of prostaglandins. Pharmacol Ther, 2000,87:61-67.
4Vanden Hoek T, Becker LB, Shao ZH, et al. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion . Circ Res, 2000,86:541-548.
5Hagar JM, Hale SL, Kloner RA.Effect of preconditioning ischemia on reperfusion arrhythmias after coronary occlusion and reperfusion in the rat. Circ Res, 1991,68:61-68.
6O'Rourke B. Myocardial K(ATP) channels in preconditioning. Circ Res, 2000, 87:845-855.
7Liu HR, Tao L,Gao E, et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res, 2004, 62: 135-144.
8Wayman NS, Hattori Y,McDonald MC,et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J, 2002, 16: 1027-1040.
9Higuchi M, Aggarwal BB, Yeh ET. Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function. J Clin Invest, 1997,99: 1751-1758.
10Communal C, Sumandea M, de Tombe P, et al. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A, 2002, 99:6252-6256.
1Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferators activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest,2000,106:523-531.
2Chen Z,Tshibashi S,Perry S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vase Biol,2001,21:372-377.
3Koshiyama H,Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes, J Clin Endocrinol Metab, 2001,86:3452-3456.
4Garay-Sevila ME, Regalado JC, Malacara JM, et al. Advanced glycosylation end products in skin,serum,saliva and urine and its association with complications of patients with type 2 diabetes mellitus, J Endocrinol Invest, 2005,28:223-230.
5Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapcutic implications of endogenous soluble form of receptor for advanced glycation end products(RAGE) in diabetes. J Cun Drug Targets,2007,8:1138-1143.
6Basta G,Schmidt AM,De-Caterina R. Advanced glycation end products and vascular inflammation:implications for accelerated atherosclerosis in diabetes. Cardiovasc Res, 2004, 63:582-592.
7Thomas MC,Baynes JW,Thorpe SR,et al. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets, 2005,6:453-474.
8Machado AP, Pinto RS, Moyses ZP, et al. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Int J Biochem Cell Biol, 2006;38:392-403.
9Passarelli M,Tang C,McDonald TO, et al. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from ceils. Diabetes, 2005,54:2198-2205.
10Yue TL,Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor γ agonist rosiglitazone. Circulation, 2001,104:588-594.
